Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gemphire Therapeutics Inc    GEMP

GEMPHIRE THERAPEUTICS INC (GEMP)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

Gemphire Therapeutics : Shares Fall Over 50% in Heavy Trading -- Market Mover

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/10/2018 | 05:19pm CEST

Gemphire Therapeutics Inc. (GEMP) saw its shares drop by over 50% in Friday trading, after the company announced the termination of a clinical trial of gemcabene. At 10:51 a.m. EDT, Gemphire shares had fallen to $1.38, down 57.80%, in heavy trading. Earlier in the week, the company announced it amended an agreement with Pfizer, Inc. concerning gemcabene. Shares opened the trading week at $7.55, and have been paused several times on Friday due to trading volatility. (stephen.nakrosis@wsj.com)

Stocks mentioned in the article
ChangeLast1st jan.
GEMPHIRE THERAPEUTICS INC -8.47% 1.43 Delayed Quote.-79.61%
PFIZER -1.51% 44.5 Delayed Quote.20.87%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GEMPHIRE THERAPEUTICS INC
09/26GEMPHIRE THERAPEUTICS : Announces Workforce Reduction
AQ
09/24Gemphire Therapeutics Announces Workforce Reduction
GL
09/24GEMPHIRE THERAPEUTICS INC. : Costs Associated with Exit or Disposal Activities, ..
AQ
08/17GEMPHIRE THERAPEUTICS : Announces Termination of Phase 2a Clinical Trial of Gemc..
AQ
08/14GEMPHIRE THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
AQ
08/13GEMPHIRE THERAPEUTICS INC. : Results of Operations and Financial Condition, Fina..
AQ
08/13Gemphire Therapeutics Reports Second Quarter 2018 Financial Results and Provi..
GL
08/11GEMPHIRE THERAPEUTICS : shares plunge on forced termination of late-stage clinic..
AQ
08/11GEMPHIRE THERAPEUTICS : Announces Termination of Phase 2a Clinical Trial of Gemc..
AQ
08/10GEMPHIRE THERAPEUTICS INC. : Regulation FD Disclosure, Other Events, Financial S..
AQ
More news
News from SeekingAlpha
10/08HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (10/08/2018) 
10/02NASH players under pressure following Liver Meeting abstract drop 
09/27HighTide's HTD1801 Fast Track'd for PSC 
09/27Tiziana Life Sciences Plans To Raise $16 Million In U.S. IPO 
09/24After Hours Gainers / Losers (09/24/2018) 
Financials ($)
Sales 2018 -
EBIT 2018 -26,2 M
Net income 2018 -30,3 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 0
Capi. / Sales 2019 0
Capitalization 22,0 M
Chart GEMPHIRE THERAPEUTICS INC
Duration : Period :
Gemphire Therapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GEMPHIRE THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 3,33 $
Spread / Average Target 116%
EPS Revisions
Managers
NameTitle
Steven R. Gullans President, CEO, CFO, CAO & Director
Charles L. Bisgaier Chairman & Chief Scientific Officer
P. Kent Hawryluk Independent Director
Kenneth Kousky Independent Director
Pedro Lichtinger Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
GEMPHIRE THERAPEUTICS INC-79.61%22
GILEAD SCIENCES1.59%96 150
VERTEX PHARMACEUTICALS20.99%45 720
REGENERON PHARMACEUTICALS2.18%41 951
NEUROCRINE BIOSCIENCES, INC.41.84%10 366
SAREPTA THERAPEUTICS INC136.05%9 222